Advanced Solid Tumors Clinical Trials in Huntersville, North Carolina

8 studies are recruiting for advanced solid tumors in Huntersville, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. GenSci143 in Participants With Advanced Solid Tumors

   A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina Biooncology Institute, Huntersville, North Carolina

   Locations

   13 in total

   Run by

   Changchun GeneScience Pharmaceutical Co., Ltd.

   See if you can join NCT07252414 on ClinicalTrials.gov

2. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

   The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville, North Carolina

   Locations

   9 in total

   Run by

   EMD Serono Research & Development Institute, Inc.

   See if you can join NCT07360314 on ClinicalTrials.gov

3. A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute /ID# 283064, Huntersville, North Carolina

   Locations

   3 in total

   Run by

   AbbVie

   See if you can join NCT07807956 on ClinicalTrials.gov

4. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

   Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   15 in total

   Run by

   Ensem Therapeutics

   See if you can join NCT06993844 on ClinicalTrials.gov

5. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

   The purpose of this study is to determine the subcutaneous (SC) dose that gives rilvegostomig exposure comparable to the intravenous (IV) exposure, and to evaluate the pharmacokinetics (PK) and safety of SC rilvegostomig in adult participants with advanced solid tumors previously treated with stand…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Huntersville, North Carolina

   Locations

   11 in total

   Run by

   AstraZeneca

   See if you can join NCT07161414 on ClinicalTrials.gov

6. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

   The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   39 in total

   Run by

   ModernaTX, Inc.

   See if you can join NCT05533697 on ClinicalTrials.gov

7. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

   The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Teva Investigational Site 12014, Huntersville, North Carolina

   Locations

   12 in total

   Run by

   Teva Branded Pharmaceutical Products R&D LLC

   See if you can join NCT06480552 on ClinicalTrials.gov

8. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

   This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Carolina BioOncology Institute, Huntersville, North Carolina

   Locations

   17 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT06040541 on ClinicalTrials.gov